Quantcast

Has anybody tried TH-302?


#1

Apparently results from a phase II study were encouraging and they are starting a phase III study:

http://www.onclive.com/publications/Oncology-live/2013/September-2013/Promising-TH-302-Results-Accelerate-Sarcoma-Study

Details about the trial are here:

http://clinicaltrials.gov/ct2/show/NCT01440088


#2

Thanks for that Elodie, always appreciate the info you post.

Kind Regards

Karen


#3

Thank you for sharing.

I just want to double check with you to make sure I understand right. Is patient allowed to participate in the trial for TH-302 alone if he got ifo-doxo two years ago?

Thank you in advance.


#4

Townclerk, how is your husband doing now? I just found out that Merck decided not to pursue TH-302 (evofosfamide) further:

http://www.emdgroup.com/emd/media/news_releases/news_releases.html


#5

I was really hoping this drug would become another option :-( I am wondering what happens to the patients who are still on it...


#6

The results of the TH-302 trial were announced and they are very disappointing:

http://www.targetedonc.com/news/maestro-trial-shows-evofosfamide-provides-little-benefit-in-sts


#7

Combining Evofosfamide (TH-302) and Doxorubicin turned out to be inefficient for soft tissue sarcoma except for synovial sarcoma in a phase 3 trial where overall survival for the combination was 22.1 months compare to 9.4 months with Doxorubicin alone:


An additional trial would be needed to confirm that it wasn’t just the luck of the draw…